Despite decades of clinical efforts targeting glycemic control and renin-angiotensin system blockade, diabetic kidney disease (DKD) remains responsible for nearly half of global ESKD cases [39], underscoring critical gaps in current therapeutic strategies. This evidence concerns the gene REN and diabetic kidney disease.